Recent blog posts
Biotinidase deficiency Indication Strategy Report 2026: BTD, Trials and Deals
Latest Hotspot
8 min read
Biotinidase deficiency Indication Strategy Report 2026: BTD, Trials and Deals
23 July 2026
2026 Biotinidase deficiency strategy: epidemiology, BTD biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Read →
Agoraphobia Indication Strategy Report 2026: GABA-A receptor, Trials and Deals
Latest Hotspot
8 min read
Agoraphobia Indication Strategy Report 2026: GABA-A receptor, Trials and Deals
23 July 2026
2026 Agoraphobia strategy: epidemiology, GABA-A receptor biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Read →
Social anxiety disorder Indication Strategy Report 2026: SERT, Trials and Deals
Latest Hotspot
8 min read
Social anxiety disorder Indication Strategy Report 2026: SERT, Trials and Deals
23 July 2026
2026 Social anxiety disorder strategy: epidemiology, SERT biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Central sleep apnea Indication Strategy Report 2026: Carbonic anhydrase, Trials and Deals
Latest Hotspot
8 min read
Central sleep apnea Indication Strategy Report 2026: Carbonic anhydrase, Trials and Deals
23 July 2026
2026 Central sleep apnea strategy: epidemiology, Carbonic anhydrase biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Panic disorder Indication Strategy Report 2026: GABA-A receptor, Trials and Deals
Latest Hotspot
8 min read
Panic disorder Indication Strategy Report 2026: GABA-A receptor, Trials and Deals
23 July 2026
2026 Panic disorder strategy: epidemiology, GABA-A receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Obstructive sleep apnea Indication Strategy Report 2026: HIF-1 alpha, Trials and Deals
Latest Hotspot
8 min read
Obstructive sleep apnea Indication Strategy Report 2026: HIF-1 alpha, Trials and Deals
23 July 2026
2026 Obstructive sleep apnea strategy: epidemiology, HIF-1 alpha biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
REM sleep behavior disorder Indication Strategy Report 2026: alpha-synuclein, Trials and Deals
Latest Hotspot
8 min read
REM sleep behavior disorder Indication Strategy Report 2026: alpha-synuclein, Trials and Deals
23 July 2026
2026 REM sleep behavior disorder strategy: epidemiology, alpha-synuclein biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Long COVID Indication Strategy Report 2026: IL-6, Trials and Deals
Latest Hotspot
8 min read
Long COVID Indication Strategy Report 2026: IL-6, Trials and Deals
23 July 2026
2026 Long COVID strategy: epidemiology, IL-6 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with PatSnap…
Read →
Chronic fatigue syndrome Indication Strategy Report 2026: P2X7, Trials and Deals
Latest Hotspot
8 min read
Chronic fatigue syndrome Indication Strategy Report 2026: P2X7, Trials and Deals
23 July 2026
2026 Chronic fatigue syndrome strategy: epidemiology, P2X7 biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Autoimmune autonomic ganglionopathy Indication Strategy Report 2026: alpha3 nAChR, Trials and Deals
Latest Hotspot
8 min read
Autoimmune autonomic ganglionopathy Indication Strategy Report 2026: alpha3 nAChR, Trials and Deals
23 July 2026
2026 Autoimmune autonomic ganglionopathy strategy: epidemiology, alpha3 nAChR biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Lambert-Eaton myasthenic syndrome Indication Strategy Report 2026: VGCC, Trials and Deals
Latest Hotspot
8 min read
Lambert-Eaton myasthenic syndrome Indication Strategy Report 2026: VGCC, Trials and Deals
23 July 2026
2026 Lambert-Eaton myasthenic syndrome strategy: epidemiology, VGCC biology, clinical competition, recent deals, unmet need and market attractiveness.
Read →
Stiff person syndrome Indication Strategy Report 2026: GAD65, Trials and Deals
Latest Hotspot
8 min read
Stiff person syndrome Indication Strategy Report 2026: GAD65, Trials and Deals
23 July 2026
2026 Stiff person syndrome strategy: epidemiology, GAD65 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Read →